Dimerix Chief Scientist awarded Novartis Prize
The Chief Scientific Advisor at Dimerix (ASX:DXB), an Australian biotechnology company developing technology for better diagnoses and treatment of chronic kidney disease (CKD), has been awarded the Novartis Prize by the British Pharmacological Society.
The award was given to Professor Kevin Pfleger for his “pioneering research, including the discovery of Dimerix’s lead development program, DMX-200”, currently undergoing clinical trials.
DMX-200 combines irbesartan and propagermanium in the treatment of chronic kidney disease (CKD) and has been shown to improve the outcome of CKD by reducing proteinuria by more than 50% in animal tests.
Professor Pfleger is also the co-inventor of the Receptor-HIT technology assigned to Dimerix from The University of Western Australia. Receptor-HIT was used to identify the DMX-200 therapy in an internal drug development program, initially for the treatment of a subset of patients with chronic kidney disease. DXB is pursuing a treatment for CKD through the application of the DMX-200 therapy which is expected to serve as DXB’s flagship treatment. In addition to its own therapeutic programs, DXB also earns revenue by providing Receptor-HIT to third party pharmaceutical firms around the world.
In response to the news, DXB Executive Chairman Dr. James Williams hopes the award will serve as a validator for the development work being done by DXB, and says that, “It is great news that Kevin’s work has been recognised in this way by the British Pharmacological Society, and we congratulate Kevin on this achievement. The multiple drug programs we are now able to commercialise based on his world-leading research offer great hope to a large number of people worldwide.”
Finfeed interviewed Mr. Williams in late March 2016, discussing DXB’s kidney disease research, its recent progress as well as future plans.
Professor Pfleger has also won other prestigious awards in recent years, within biochemistry. He was named Western Australian Young Scientist of the Year 2009 and his work featured as one of the NHMRC 10 of the Best Research Projects 2010. In 2011, he was awarded the Australian Museum Eureka Prize for Emerging Leader in Science, in 2012 he won The Endocrine Society Early Investigators Award and the WA Young Tall Poppy Science Award.
Professor Pfleger will receive the Novartis prize and the US$3,000 winners prize, as part of the British Pharmacological Society’s annual meeting, held every December in London, UK.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.